Pure Red-Cell Aplasia and Epoetin Therapy

2004429 citationsJournal Articlebronze Open Access

Authors

Charles L. Bennett · Robert H. Lurie Comprehensive Cancer Center of Northwestern University

Stefano Luminari · University of Modena and Reggio Emilia

Allen R. Nissenson · University of California, Los Angeles

Martin S. Tallman · Robert H. Lurie Comprehensive Cancer Center of Northwestern University

Stephen A. Klinge · Northwestern University

Norene McWilliams · Northwestern University

Abstract

After the peak incidence of Eprex-associated pure red-cell aplasia was reached in 2001, interventions designed in response to drug-monitoring programs worldwide resulted in a reduction of more than 80 percent in the incidence of pure red-cell aplasia due to Eprex.

Topics & Keywords

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: New England Journal of Medicine

Volume 351, Issue 14, pp. 1403-1408

DOI: 10.1056/nejmoa040528

Field-Weighted Citation Impact: 11.02